史美倫:科技及生科公司將持續錄強勁增長 對今年經濟樂觀
港交所(00388.HK)主席史美倫於亞洲金融論壇上表示,中國經濟於新型肺炎疫情後大幅增長,本港作為聯繫中國及國際的角色亦將受惠。她又指,疫情改變大眾生活習慣,相信生物科技及科技公司將會持續錄得強勁增長。
她指,港交所對今年經濟環境樂觀,由於新型肺炎疫苗已研發成功及廣泛接種。她指去年大部份首次上市集資額來自新經濟及生物科技公司。另外,現時企業亦較為著重可持續發展及「環境、社會和企業管治(ESG)」方面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.